Meeting
2016 ASCO Annual Meeting
Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.
Authors
Guillermo de Velasco
Dana-Farber Cancer Institute, Boston, MA
Guillermo de Velasco , Youjin Je , Mark M. Awad , Patrick Alexander Ott , Fabio Augusto Barros Schutz , Joaquim Bellmunt , Guru Sonpavde , F. Stephen Hodi , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3068)
DOI
10.1200/JCO.2016.34.15_suppl.3068
Abstract #
3068
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy.
First Author: Kate E Lee
Poster
2020 ASCO Virtual Scientific Program
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.
First Author: David E. Kozono
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde